Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).

DISEASE CHARACTERISTICS: * Histologically confirmed non-small cell lung cancer of the following non-squamous subtypes: * Adenocarcinoma * Bronchioloalveolar carcinoma * Large cell carcinoma * Stage IV disease including any of the following: * M1a (separate tumor nodule in a contralateral lobe, tumor with pleural nodules, or malignant pleural or pericardial effusion) * M1b (distant metastasis) * Measurable disease, defined as ≥ 1 lesion (outside of irradiated areas) that can be measured in ≥ 1 dimension as ≥ 10 mm (≥ 15 mm in case of lymph nodes) according to RECIST 1.1 * Paraffin-embedded or formalin-fixed diagnostic biopsy collected in the past 2 months must be available * Must have EGFR-mutation status (mutated or wild type) confirmed by the central pathologist in Basel * Must consent to tumor biopsy at progression * No intrathoracic tumors invading or abutting major blood vessels * No CNS metastases by mandatory CT scan (MRI within the past 3 weeks is acceptable) PATIENT CHARACTERISTICS: * WHO performance status 0-1 * Hemoglobin ≥ 100 g/L * ANC ≥ 1,500/mm³ * Platelet count ≥ 100,000/mm³ * Bilirubin ≤ 1.5 times upper limit of normal (ULN) * ALT ≤ 3 times ULN (≤ 5 times ULN if liver metastases are present) * Alkaline phosphatase ≤ 3 times ULN (≤ 5 times ULN if liver metastases are present) * Calculated creatinine clearance ≥ 60 mL/min * Urine dipstick for proteinuria \< 2+ * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effectiv…